📰 True Human News
Page 2 - True Human News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from True Human. Real-time updates on events, politics, business and more.
November 15, 2023
StockNews.com began coverage on shares of XBiotech (NASDAQ:XBIT – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. XBiotech Price Performance Shares of XBIT stock opened at $3.81 on Friday. The business’s 50 day simple moving average is $4.18 and its 200 […]
September 26, 2023
AUSTIN, Texas, Sept. 26, 2023 -- XBiotech Inc. Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a...
September 26, 2023
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after...
August 20, 2023
StockNews.com assumed coverage on shares of XBiotech (NASDAQ:XBIT – Free Report) in a research note released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. XBiotech Stock Performance XBiotech stock opened at $5.00 on Thursday. The stock has a market capitalization of $152.20 million, a price-to-earnings ratio of -4.20 and […]
August 18, 2023
StockNews.com began coverage on shares of XBiotech (NASDAQ:XBIT – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. XBiotech Trading Up 4.9 % Shares of NASDAQ XBIT opened at $5.10 on Thursday. The business’s 50 day moving average price is $5.45 and […]
August 8, 2023
AUSTIN, Texas, Aug. 08, 2023 -- XBiotech Inc. today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new...
May 22, 2023
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 -- XBiotech Inc. today reports that the FDA’s Division of Rheumatology... | May 22, 2023
May 22, 2023
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA's Division of
April 18, 2023
XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is being developed as a novel treatment to reduce brain injury following ischemic stroke. There are more than 10 ...
April 17, 2023
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 -- XBiotech Inc. has enrolled the first subject in a... | April 17, 2023